Jeito Capital

Rafaèle Tordjman, the founder and CEO, leads the investment committee. A physician by training who previously served as a managing partner at Sofinnova Partners, she built the firm around her scientific and clinical network. Jeito also convenes a scientific advisory board of European clinicians and former regulators who inform diligence on therapeutic-area viability and reimbursement pathways.

Jeito writes initial equity checks between €15 million and €50 million, targeting European biopharma companies that have already generated clinical data and require growth capital to advance toward regulatory approval. The firm reserves significant reserves for follow-on rounds and maintains a long-duration investment horizon designed to carry companies through clinical inflection points.

Jeito sources primarily through founder Rafaèle Tordjman's relationships across European academic medical centers, biotech clusters, and the venture ecosystem she accessed during her tenure at Sofinnova Partners. The firm's scientific advisory board — composed of clinicians and former regulators — also surfaces therapeutic-area opportunities. Jeito does not operate a public deal-submission portal and has described its sourcing as relationship-driven and science-led.

Jeito's mandate concentrates on Western European biopharma companies, with active portfolio construction in France, the UK, and the Benelux region. The firm has not publicly disclosed investments in North American or Asian-headquartered companies, though portfolio companies often pursue US regulatory filings and commercial partnerships as part of Jeito's exit strategy.

Yes. Jeito requires portfolio companies to articulate a European patient-access strategy at the term-sheet stage — a governance feature that distinguishes the firm from most venture and growth equity investors. The covenant reflects Tordjman's medical background and the firm's thesis that reimbursement planning must run parallel to clinical development, not after it.

Jeito operates a multi-LP fund structure. Its debut vehicle closed above €350 million with backing from institutional investors including the European Investment Fund. The firm's second fund, Jeito II, targeted €500 million and held a first close above €200 million in May 2023 (per Private Equity News, May 2023).

Jeito's portfolio spans oncology, rare diseases, and neurology, with confirmed investments in immunotherapy, ocular gene therapy, and TCR cell therapy. The firm has publicly disclosed no investments in medical devices, diagnostics, or digital health — its concentration remains on biopharmaceutical platform companies and therapeutic assets that require clinical-trial execution and regulatory navigation.